medigraphic.com

2002, Number 1

<< Back

Arch Cardiol Mex 2002; 72 (1)

Hypertension in mexico: the Health National Survey 2000

Velázquez MO, Rosas PM, Lara EA, Pastelín HG, Attie F, Tapia CR

Language: Spanish
References: 56
Page: 71-84
PDF size: 424.74 Kb.


ABSTRACT

Aims. Hypertension remains as a major cause of cardiovascular morbidity in México. The Health National Survey 2000 of México was performed to analyze the current status of the prevalence of some risk factors such as diabetes, hypertension (HTA), obesity, smoking, and proteinuria. Methods. A National Survey was carried out in México where 45,300 individuals between 20 to 69-y.o. were screened. The estimated sample size was calculated considering the total number of persons into the mentioned age; a minimal prevalence of 6% of the included risk factors, at a significance level of 0.05; a maximum relative error of 0.145, and a rate of response of at least 70%. Diagnosis of HTA was accepted in: previous medical diagnosis with prescription of antihypertensive drugs, or high blood pressure (≥ 140/90 mmHg) detected during the interview. Data were adjusted for the national distribution of age-groups and gender (established in 2000, INEGI). Results. 38,377 (98.8%) individuals were correctly screened for blood pressure. The prevalence of hypertension in México was 30.05% (34.2% in men and 26.3% in women). The prevalence was directly related with age and gender. The percentage of mexicans with HTA after 50-y.o. is › 50%. The prevalence was greater in women after 50-y.o. Among persons with hypertension, treatment was detected in 46% and ~ 20% of them were controlled (‹140/90mmHg). The percentage of mexicans with HTA who were unaware that they have high blood pressure was 61%. The total percentage of HTA controlled was 14.6%. The North states had the greater prevalence (~ 34%) of HTA while South states had the lower prevalence (27%). The odds ratio (age/sex-adjusted) for HTA were: for diabetes 1.54(CI95%, 1.44 – 1.63); for obesity 2.3 (CI 95%, 2.22 – 2.43); for smoking 1.26 (CI95%, 1.21 – 1.32). For proteinuria subjects, 40% had HTA. Conclusions. Around 15 millions of mexicans between 20 to 69-y.o. had hypertension, 60% of them are unaware. The prevalence of hypertension in México (30.05%) has increased. Among persons with hypertension ~ 15% are controlled. The North of México has the higher prevalence of hypertension. Diabetes, smoking, and obesity increase the risk of hypertension. The 2000 National Survey of Health shows the epidemiological trend in several important chronic diseases in México and declare an urgent need of new strategies for detection, control and treatment of hypertension.


REFERENCES

  1. Cardiovascular Diseases. WHO: http://www.who.

  2. int/ncd/cvd/CardioBroch.pdf 2002.

  3. Murray CJL, Lopez AD: Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997; 349: 1269-1276.

  4. Causas de Mortalidad en México 2000. Estadísticas de Mortalidad, Secretaría de Salud. http://www.ssa.gob.mx

  5. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood Pressure, stroke and coronary artery disease. Part 2. Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.

  6. Lenfant C: Reflections of hypertension control rates. Arch Intern Med 2002; 162: 131-132.

  7. User´s Guide: SPSS for windows. Advanced Statistics release 10.0 Chicago: SPSS; 1999. p. 285-310.

  8. Chalmers J: WHO-ISH Hypertension Guidelines Committee. 1999 World Health organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 1999; 17: 151-185.

  9. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, Williams K, Gonzalez-Villalpando C, Stern MP, Hazuda HP, Haffner S: Prevalence of hypertension in Hispanic and non-Hispanic white populations. Hypertension 2002; 39: 203-8.

  10. National High Blood Pressure Education Program, NIH; NHLBI: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Nov 1997;1-64. http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm.

  11. Cooper RS, Rotimi CN, Kaufman JS, Muna WFT, Mensah GA: Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy. BMJ 1998; 316: 614-617.

  12. Duprez D, Van Helshoecht P, Van Den Eynde W, Leeman M: Prevalence of hypertension in the adult population of Belgium: report of a worksite study, attention hypertension. J Hum Hypertens 2002; 16: 47-52.

  13. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60–69.

  14. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P: Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997; 10: 1097–1102.

  15. Kaufman JS, Barkey N: Hypertension in Africa: an overview of prevalence rates and casual risk factors. Ethnic Dis 1993; 3 (suppl): S83-S101.

  16. NHLBI Urges Americans To Take Control of Their Hypertension. NIH new release. 1999. http://www.nhlbi.nih.gov/new/press/mayhbpmo.htm

  17. Arredondo A: Financial requirements for health services demands for diabetes and hypertension in Mexico: 2001-2003. Rev Invest Clin 2001; 53: 422-9.

  18. Haffner S, Villalpando CG, Hazuda HP, Valdez R, Mykkanen L, Stern M: Prevalence of hypertension in Mexico City and San Antonio, Texas. Circulation 1994; 90: 1542-1549.

  19. Arroyo P, Fernandez V, Loria A, Kuri-Morales P, Orozco-Rivadeneyra S, Olaiz G, Tapia-Conyer R: Hypertension in urban Mexico: the 1992-93 national survey of chronic diseases. J Hum Hypertens 1999; 13: 671-5.

  20. Joffres MR, Hamet P, MacLean DR, L´itallien GJ, Fodor G: Distribution of blood pressure and hypertension in Canada and the United States. AJH 2001; 14:1099-1105.

  21. Thijs L, Staessen JA, Beleva S, Birkenhager WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH: How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001; 2: 298-306.

  22. Chae CU, Lloyd-Jones DM: Isolated Systolic Hypertension in the Elderly. Current treatment options in cardiovascular medicine. 2002; 4: 87-93.

  23. Gasowski J, Staessen JA, Celis H, Fagard RH, Thijs L, Birkenhager WH, Bulpitt CJ, Fletcher AE, Arabidze GG, de Leeuw P, Dollery CT, Duggan J, Kawecka-Jaszcz K, Leonetti G, Nachev C, Safar M, Rodico JL, Rosenfeld J, Seux ML, Tuomilehto J, Webster J, Yodfat Y: Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators. J Hum Hypertens. 1999; 13: 135-45.

  24. Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Gregoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R, behalf of the Syst-Eur Investigators. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract 1996; 13: 138-43.

  25. Wang JG, Staessen JA: The benefit of treating isolated systolic hypertension. Curr Hypertens Rep 2001; 3: 333-9.

  26. Stanton T, Reid JL: Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens 2002; 16: 75-8.

  27. Oparil S: Are there meaningful differences in blood pressure control with current antihypertensive agents? Am J Hypertens 2002; 15(1 Pt 2): 14S-21S.

  28. Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation 2000; 101: 329-35.

  29. Carretero OA, Oparil S: Essential hypertension: part II: treatment. Circulation 2000; 101: 446-53.

  30. Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, Sakkinen PA, Lyles MF, Spurgeon HA, Lakatta EG, Kuller LH: Correlates of aortic stiffness in elderly individuals: a subgroup of the Cardiovascular Health Study. Am J Hypertens 2002; 15(1 Pt 1): 16-23.

  31. Franco V, Oparil S: Hormone replacement therapy and hypertension. Curr Opin Nephrol Hypertens 2002; 11: 229-35.

  32. Borde-Perry WC, Campbell KL, Murtaugh KH, Gidding S, Falkner B: The association between hypertension and other cardiovascular risk factors in young adult African Americans. J Clin Hypertens 2002; 4: 17-22.

  33. Rangarajan U, Kochar MS: Hypertension in women. WMJ 2000; 99: 65-70.

  34. Hayes SN, Taler SJ: Hypertension in women: current understanding of gender differences. Mayo Clin Proc 1998; 73: 157-65.

  35. August P, Oparil S: Hypertension in women. J Clin Endocrinol Metab 1999; 84: 1862-6.

  36. Legato MJ: Cardiovascular disease in women: gender-specific aspects of hypertension and the consequences of treatment. J Womens Health 1998; 7: 199-209.

  37. Jandeleit-Dahm K, Cooper ME: Hypertension and diabetes. Curr Opin Nephrol Hypertens 2002; 11: 221-8.

  38. Waeber B, Feihl F, Ruilope L: Diabetes and hypertension. Blood Press 2001; 10: 311-21.

  39. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9.

  40. Drury PL: Diabetes and arterial hypertension. Diabetologia 1983; 24: 1-9.

  41. Fuller JH: Hypertension and diabetes: epidemiologic aspects as a guide to management. J Cardiovasc Pharmacol 1993; 21(Suppl 2): S63-6.

  42. Weir MR: Diabetes and hypertension: how low should you go and with which drugs? Am J Hypertens 2001; 14(5 Pt 2): 17S-26S.

  43. Halimi JM, Giraudeau B, Vol S, Caces E, Nivet H, Tichet J: The risk of hypertension in men: direct and indirect effects of chronic smoking. J Hypertens 2002 Feb; 20: 187-193.

  44. Ernster VL, Grady D, Miike R, Black D, Selby J, Kerlikowske K: Facial wrinkling in men and women, by smoking status. Am J Public Health 1995; 85: 78-82.

  45. Halimi JM, Giraudeau B, Vol S, Caces E, Nivet H, Lebranchu Y, Tichet J: Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285-92.

  46. Flegal KM, Troiano RP, Pamuk ER, Kuczmarski RJ, Campbell SM: The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995; 333: 1165-70.

  47. Wannamethee G, Shaper AG: Body weight and mortality in middle aged British men: impact of smoking. BMJ 1989; 299: 1497-502.

  48. Arroyo P, Fernandez V, Avila-Rosas H: Overweight and hypertension: data from the 1992-1993 Mexican survey. Hypertension 1997; 30: 646-9.

  49. Colin Bell A, Adair LS, Popkin BM: Ethnic Differences in the Association between Body Mass Index and Hypertension. Am J Epidemiol 2002; 155: 346-53.

  50. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

  51. James PT, Leach R, Kalamara E, Shayeghi M: The worldwide obesity epidemic. Obes Res 2001; 9 Suppl 4: 228S-233S.

  52. Motala AA, Pirie FJ, Gouws E, Amod A, Omar MA: Microvascular complications in South African patients with long-duration diabetes mellitus. S Afr Med J 2001; 91: 987-92.

  53. Curtis B, Barrett BJ, Levin A: Identifying and slowing progressive chronic renal failure. Can Fam Physician 2001; 47: 2512-8.

  54. Sica DA, Douglas JG: The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens 2001; 3: 244-51.

  55. Pisoni R, Remuzzi G: How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? J Nephrol 2000; 13: 228-31.

  56. Remuzzi G: Renal protection: progression, regression, remission from nephropathy beyond blood pressure control. Int J Clin Pract Suppl 2000; 110: 9-15.




2020     |     www.medigraphic.com